StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research report report published on Friday. The firm issued a sell rating on the stock.
Bio-Path Stock Performance
NASDAQ:BPTH opened at $1.16 on Friday. The firm has a 50-day simple moving average of $0.90 and a 200-day simple moving average of $1.20. Bio-Path has a one year low of $0.59 and a one year high of $12.00.
Institutional Trading of Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- How to buy stock: A step-by-step guide for beginners
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- Financial Services Stocks Investing
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- ETF Screener: Uses and Step-by-Step Guide
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
